Total 158, page 7/8
No. | Organization | Therapeutic Area | Product Type | Title |
---|---|---|---|---|
38 | University of Illinois at Chicago | Immunology | Protein | OX40L-Jagged-1-Fc, for the In Vivo Expansion of Treg Cells |
37 | University of California, San Francisco | Oncology | Antibody | Novel Tumor Selective Internalizing Antiboies |
36 | University of California, San Francisco | Cardiovascular disease | Small molecule | Covalent Activators Of K2p Channels |
35 | University of California, San Diego | Oncology, Infectious disease | Small molecule | Small Molecule, TLR-4 Ligands as Immonomodulators |
34 | University of California, San Diego | Oncology | Vaccine | Encapsulation Method of Adenoviral Vectors in Liposomes |
33 | University of California, San Diego | Inflammatory disease | Small molecule | Identification of Novel NLRP3 Inflammasome Inhibitors |
32 | University of California, San Diego | Oncology | Cell therapy | Macrophage Programming for Immunotherapy |
31 | University of California, San Diego | Oncology | Small molecule | Novel Cyclic Dinucleotide Analogues as STING Agonists |
30 | The Ohio State University | Oncology, Hematology | Small molecule | HOSU-3, DHODH Inhibitor for Acute Myeloid Leukemia |
29 | The Ohio State University | Oncology | Small molecule | AHR Inhibitor for Hematological Malignancies |
28 | The Ohio State University | Oncology | Small molecule | Mps1 Kinase Inhibitors As Mitotic Regulator for Cancer Therapy |
27 | The Ohio State University | Hematology | Small molecule | DHODH Inhibitors for Treatment of Hematological Malignancies |
26 | The Ohio State University | Oncology | Vaccine | Activated B cells as Therapeutic Cancer Vaccine Platform |
25 | The Ohio State University | Oncology | Small molecule | Orally Bioavailable and Brain Penetrant Mps1/TTK inhibitors as cancer therapeutics |
24 | The Ohio State University | Oncology | Small molecule | STAT3 Inhibitors and Their Anti-Cancer Usage |
23 | The Ohio State University | Immunology, Oncology | Antibody | Improving Immunotherapy with mRNA Delivery |
22 | Stanford University | Genetic disorders | Gene therapy | S06-098: Novel AAV capsids with new transduction and nonimmune properties |
21 | Stanford University | Immunology, Oncology | Cell therapy | MicroRNA Expression in Dendritic Cells for Immune Regulation |
20 | Stanford University | Oncology | Antibody | Methods to Treat Malignant Pediatric Brain Tumors Using Anti-CD47 Agents |
19 | Stanford University | Ophthalmology | Gene therapy | miR-494 inhibitor, for the treatment of retinal disease |